Edition:
United Kingdom

Resverlogix's Betonmace Phase 3 Trial Reaches Its Targeted 250 Major Adverse Cardiac Events


Thursday, 18 Apr 2019 

April 18 (Reuters) - Resverlogix Corp ::RESVERLOGIX'S BETONMACE PHASE 3 TRIAL SUCCESSFULLY REACHES ITS TARGETED 250 MACE EVENTS.RESVERLOGIX CORP - BETONMACE EVENT-BASED, PHASE 3 REGISTRATION TRIAL HAS SUCCESSFULLY REACHED 250 PROJECTED MAJOR ADVERSE CARDIAC EVENTS.RESVERLOGIX CORP - SUCCESSFUL DATA FROM TRIAL WOULD ENABLE RESVERLOGIX TO PROCEED TOWARDS REGULATORY APPROVAL. 

Company Quote

2.82
0.06 +2.17%
5:06pm BST